Scarica l'app Stockscreener
7.17
2.18%
-0.16
Precedente Chiudi:
$7.33
Aprire:
$7.13
Volume 24 ore:
259.61K
Relative Volume:
1.18
Capitalizzazione di mercato:
$440.98M
Reddito:
-
Utile/perdita netta:
$-38.61M
Rapporto P/E:
-7.23
EPS:
-0.9917
Flusso di cassa netto:
$-29.20M
1 W Prestazione:
+4.67%
1M Prestazione:
-13.61%
6M Prestazione:
+19.50%
1 anno Prestazione:
+119.27%
Intervallo 1D:
$6.985
$7.41
Intervallo di 1 settimana:
$6.56
$7.62
Portata 52W:
$2.6801
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Nome
Eupraxia Pharmaceuticals Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.17 | 440.98M | 0 | -38.61M | -29.20M | -0.9917 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Iniziato | William Blair | Outperform |
| 2025-07-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2025-06-16 | Iniziato | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Iniziato | Craig Hallum | Buy |
| 2024-11-14 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Eupraxia Pharmaceuticals Inc Borsa (EPRX) Ultime notizie
Top iBio (IBIO) Competitors 2026 - MarketBeat
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - stocktitan.net
New strong sell stocks for April 2nd - msn.com
ETFs Investing in Eupraxia Pharmaceuticals, Inc. Stocks - TradingView
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March - MarketBeat
Eupraxia Pharmaceuticals Projected to Post Earnings on Tuesday - National Today
Eupraxia Pharmaceuticals boasts $900 million peak sales potential: Analyst - MSN
Risk Recap: What is Eupraxia Pharmaceuticals Incs valuation compared to sectorVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Aug Chart Watch: Whats the beta of Eupraxia Pharmaceuticals Inc stockMarket Movers & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday - MarketBeat
Eupraxia Pharmaceuticals: Analyst Expects $900M In Peak SalesEupraxia Pharmaceuticals (NASDAQ:EPRX) - Benzinga
William Blair Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) - MarketBeat
Eupraxia Pharmaceuticals Inc.: Fundamental Analysis and Financial Ratings | X43 | CA29842P1053 - marketscreener.com
If You Invested $1,000 in Eupraxia Pharmac (EPRX) - stocktitan.net
You need to know this Canadian biotech stock, analyst says - Cantech Letter
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Lifesci Capital Has Negative Outlook of EPRX FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for EPRX Q1 Earnings? - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Zacks Research - MarketBeat
Profit Recap: Will Eupraxia Pharmaceuticals Inc stock hit new highs in YEAR2026 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Q2 Earnings Estimate for EPRX Issued By HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Given New $11.00 Price Target at HC Wainwright - Defense World
EPRX stock on retail radar after strong remission data in digestive disease trial - MSN
Buyout Rumor: Whats BioXcel Therapeutics Incs historical return2026 Trade Ideas & High Accuracy Swing Entry Alerts - baoquankhu1.vn
H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Investing News Network
Eupraxia Pharmaceuticals Stock Surges on Drug Trial Win - TipRanks
A Little-Known Biotech Is Gaining Retail Buzz With Its Latest Trial Data - Stocktwits
H.C. Wainwright cuts Eupraxia Pharmaceuticals price target on higher costs - Investing.com
EPRX Stock On Retail Radar After Strong Remission Data In Digestive Disease Trial - menafn.com
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
HC Wainwright Has Lowered Expectations for Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price - MarketBeat
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances - tipranks.com
Eupraxia (EPRX) shows strong symptom gains, clean safety in RESOLVE EoE trial - Stock Titan
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data - GlobeNewswire
Freedman lifts Eupraxia (EPRX) stake to 9% after 2026 share purchases - Stock Titan
Aug Reactions: Is Eupraxia Pharmaceuticals Inc affected by consumer sentiment2026 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Rises By 19.4% - MarketBeat
Ally Bridge Group NY LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX - MarketBeat
(EPRX) Technical Data (EPRX:CA) - Stock Traders Daily
Cantor Fitzgerald Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail
Eupraxia Pharmaceuticals (NASDAQ: EPRX) files 2025 Form 40-F with audited statements - Stock Titan
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results - Investing News Network
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing - TipRanks
Eupraxia testing EoE drug extends cash runway to 2028 - Stock Titan
Eupraxia Pharmaceuticals Inc Azioni (EPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):